# TVTX earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/TVTX) · [Earnings tab](https://www.lopjlb.com/stock/TVTX?tab=earnings) Updated: 2026-11-02T05:13:01 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarterly CallCards, Travere’s narrative shifted from vague guidance in 2024 to concrete commercial and regulatory milestones by 2026. Early signals in late‑2024 highlighted strong FILSPARI sales after full IgAN approval and a planned FSGS sNDA. By Q2 2025, sales accelerated (+82% YoY), new patient starts rose 43%, and the company reported non‑GAAP profitability, low gross‑to‑net discounts and a disciplined cash burn. Regulatory momentum built through REMS modifications, a PDUFA target for the FSGS sNDA, and eventual FDA approval in Q1 2026. Concurrently, the HARMONY study for pegtibatinase was paused, then restarted, with manufacturing scale‑up progressing. Throughout 2025‑2026, demand for FILSPARI remained robust in both IgA nephropathy and the newly approved FSGS indication, driving record sales and expanding the prescriber base. Margin pressure modestly increased as gross‑to‑net discounts edged higher, but balance‑sheet strength persisted. Pipeline breadth grew with civorebrutinib licensing and new patent filings, while the company faced recurring regulatory, competitive, and reimbursement concerns, alongside emerging seasonality and pipeline‑result uncertainties. ## Latest CallCard · Q2 Travere reported record Q2 sales driven by strong FILSPARI demand in IgA nephropathy and an early, rapid FSGS launch, while advancing pegtibatinase, civorebrutinib and patent coverage, and reaffirmed confidence despite early‑stage uncertainties. **Guidance:** vague — Management avoided specific forecasts, noting it is early in the launch and difficult to project demand or growth. **Tone:** mgmt 0.7 · Q&A pressure 0.5 · divergence 0.3 The second quarter was exceptional, showing strength and disciplined execution, with early FSGS adoption exceeding expectations and a solid pipeline outlook. ### Demand visibility Strong demand for FILSPARI across both indications Record FILSPARI demand with over 2,000 new patient start forms and $141 million U.S. revenue; growth in IgA nephropathy despite new entrants and early FSGS adoption exceeding expectations. ### Margins / costs Mid‑20% gross‑to‑net discounts expected Q2 discounts were slightly lower; discounts are expected to rise in Q3/Q4 as more FSGS patients initiate therapy, with full‑year mid‑20% range guidance. ### Capital allocation Investing in launch, pipeline and balance‑sheet strength Capital directed to FILSPARI FSGS launch, Phase III HARMONY study, civorebrutinib licensing ($112.5 M upfront), convertible note refinancing, leaving $489.2 M cash. ### Milestones - **FILSPARI FSGS launch** [on_track]: Early adoption exceeding expectations; broad prescriber base with most physicians having a single patient. - **Pegtibatinase Phase III HARMONY study** [on_track]: Enrollment ongoing; top‑line results expected in H2 2027. - **Civorebrutinib licensing** [new]: Exclusive agreement closed; IND filing in the U.S. planned. - **Sparsentan IgA method‑of‑use patent** [delivered]: USPTO issued Notice of Allowance, providing anticipated U.S. coverage. - **Post‑transplant study enrollment** [on_track]: Enrollment completed; data anticipated in 2027. - **Phase IV study in African‑ancestry FSGS** [new]: Planned to start in H2 2026 to evaluate efficacy and safety. ### Fears / risks - **Competition**: New treatment options entering the IgA nephropathy market could pressure FILSPARI demand. - **Seasonality**: Potential summer slowdown in patient starts for FSGS. - **Payer reimbursement**: Need to educate payers and secure formulary placement may delay access. - **Pipeline uncertainty**: Phase III HARMONY results and IND filing for civorebrutinib are pending. - **Conversion uncertainty**: Unclear speed of conversion from patient start forms to paid prescriptions. - **Multi‑therapy cost concerns**: Physicians anxious about using multiple branded agents due to cost considerations. - **Patent risk**: Pending patent prosecution for FSGS method‑of‑use. - **Market penetration limits**: Penetration into the ~30,000 addressable FSGS patients may be limited by physician adoption patterns. ### Key quotes > “The second quarter was exceptional. Our performance demonstrates the strength of the company we are building and the disciplined execution of our teams.” — Eric Dube > “record FILSPARI demand with over 2,000 new patient start forms across IgA nephropathy and FSGS and record U.S. revenue of more than $141 million for the quarter.” > “We are very excited about the rapid uptake that we've seen thus far in FSGS against the backdrop of growing demand in IgA nephropathy.” — Eric Dube > “we haven't disclosed the specific on the rates of what we saw early in the conversion rate for IgA nephropathy.” — Peter Heerma ## Quarter one-liners - **2026 Q2:** Travere reported record Q2 sales driven by strong FILSPARI demand in IgA nephropathy and an early, rapid FSGS launch, while advancing pegtibatinase, civorebrutinib and patent coverage, and reaffirmed confidence despite early‑stage uncertainties. - **2026 Q1:** Travere reports Q1 2026 with FDA approval for FILSPARI in FSGS, record IgA nephropathy demand (993 PSFs), $105M FILSPARI sales, and HARMONY study restart for pegtibatinase targeting 2027 top-line data.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Management emphasizes tremendous start, pivotal FDA appr - **2025 Q4:** Travere reported record IgA nephropathy demand, strong FILSPARI sales, an FDA PDUFA target of April 13 2026 for the FSGS sNDA, and resumed Phase III enrollment for pegtibatinase, while noting modestly higher gross‑to‑net discounts and no near‑term capital needs. - **2025 Q3:** TVTX Q3: FILSPARI IgAN $90.9M (+155% YoY), REMS eased, KDIGO inclusion, FSGS PDUFA Jan 2026, pegtibatinase scale-up for 2026 HARMONY, $254.5M cash.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks emphasize exceptional progress, strong commercial execution, regulatory momentum, and confide - **2025 Q2:** Travere reports strong Q2 with FILSPARI $72M US sales (+82% YoY), 745 new patient starts (+43%), advancing FSGS sNDA (PDUFA Jan 2026) and REMS modifications (PDUFA Aug 28), cash $319M. Non-GAAP profitable. FSGS could be larger opportunity. HARMONY restart 2026. THIOLA generic risk. Gross-to-net low - **2025 Q1:** — - **2024 Q4:** Travere reports strong FILSPARI Q4 sales growth post full IgAN approval, plans FSGS sNDA submission end of Q1 2025, advances pegtibatinase manufacturing, holds $370.7M cash; no formal 2025 revenue guidance provided.','tone': {'mgmt': 0.8, 'mgmt_rationale': 'Prepared remarks emphasize "remarkable yea - **2024 Q3:** — ## Theme arcs - **FILSPARI commercial demand** (improving): IgAN sales grew from $72M to $105M and FSGS approval added new revenue stream - **Regulatory progress** (improving): sNDA submission, PDUFA target, and eventual FDA approval for FSGS - **Margin pressure** (deteriorating): Gross‑to‑net discounts rose from low‑20% to mid‑20% range - **Capital position** (stable): Cash declined from $370.7M to $254.5M but remained ample for investments - **Pipeline expansion** (new): Civorebrutinib licensing, Sparsentan patent, and multiple study initiations - **Competitive landscape** (deteriorating): Emerging IgAN therapies and generic risk for THIOLA noted - **Manufacturing scale‑up** (stable): Pegtibatinase manufacturing optimization delivered, ongoing scale‑up ## Guidance path 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:vague → 2026 Q2:vague --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/TVTX`